Differential distribution of PDE4B splice variant mRNAs in rat brain and the effects of systemic administration of LPS in their expression

Synapse

Volumn 62, Issue 1, 2008, Pages 74-79

  Reyes Irisarri, Elisabet ^a   Pérez Torres, Silvia ^a   Miró, Xavier ^b   Martínez, Emili ^a   Puigdomènech, Pere ^b   Palacios, José M ^c   Mengod, Guadalupe ^a,d  

^a INST D INVESTIGACIONS B   (Spain)

^b INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

cAMP; In situ hybridization; Inflammation; PDE4B splicing variant

Indexed keywords

CYCLIC AMP; ENDOTOXIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4B2; PHOSPHODIESTERASE B2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CHOROID PLEXUS; ENZYME LOCALIZATION; ENZYME REGULATION; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA SPLICING;

ALTERNATIVE SPLICING; ANIMALS; BRAIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; GENE EXPRESSION; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION; INFLAMMATION; ISOENZYMES; LIPOPOLYSACCHARIDES; RATS; RNA, MESSENGER;

EID: 36349027610     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20459     Document Type: Article

References (39)

1. Ahmed T, Frey JU. 2003. Expression of the specific type IV phosphodiesterase gene PDE4B3 during different phases of long-term potentiation in single hippocampal slices of rats in vitro. Neuroscience 117:627-638.
2. Bach E, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, Kandel ER. 1999. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci USA 96:5280-5285.
3. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E. 1998. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 95:15020-15025.
4. Borinson HL, Wang SC. 1953. Physiology and pharmacology of vomiting. Pharmacol Rev 5:193-230.
5. Breder CD, Saper CB. 1996. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 713:64-69.
6. Breder CD, Hazuka C, Ghayur T, Klug C, Huginin M, Yasuda K, Teng M, Saper CB. 1994. Regional induction of tumor necrosis factor α expression in the mouse brain after systemic lipopolysaccharide administration. Proc Natl Acad Sci USA 91:11393-11397.
7. Brown TH, Zador AM. 1990. Hippocampus. In: Gordon MS, editor. The synaptic organization of the brain. New York: Oxford University Press. p 346-388.
8. Brown TH, Chapman PF, Kairiss EW, Keenan CL. 1988. Long-term synaptic potentiation. Science 242:724-728.
9. Cao C, Matsumura K, Yamagata K, Watanabe Y. 1997. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. Am J Physiol 272:R1712-R1725.
10. Carpenter DO, Briggs DB, Knox AP, Strominger N. 1988. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J Neurophysiol 59:358-369.
11. Chung KF. 2006. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533:110-117.
12. D'Sa C, Eisch AJ, Bolger GB, Duman RS. 2005. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci 22:1463-1475.
13. Engels P, Fichtel K, Lubbert H. 1994. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett 350:291-295.
14. Gantner F, Götz C, Gekeler V, Schudt C, Wendel A, Hatzelmann A. 1998. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 123:1031-1038.
15. Houslay MD, Sullivan M, Bolger GB. 1998. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 44:225-342.
16. Jin SL, Conti M. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc Natl Acad Sci USA 99:7628-7633.
17. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, Conti M. 1999. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci USA 96:11998-12003.
18. Jin SL, Lan L, Zoudilova M, Conti M. 2005. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175:1523-1531.
19. Lacroix S, Rivest S. 1998. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem 70:452-466.
20. Lacroix S, Feinstein D, Rivest S. 1998. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol 8:625-640.
21. McGeer PL, McGeer EG. 1995. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21:195-218.
22. McPhee I, Cochran S, Houslay MD. 2001. The novel long PDE4A10 cyclic AMP phosphodiesterase shows a pattern of expression within brain that is distinct from the long PDE4A5 and short PDE4A1 isoforms. Cell Signal 13:911-918.
23. Menniti FS, Faraci WS, Schmidt CJ. 2006. Phosphodiesterases in the CNS: Targets for drug development. Nat Rev Drug Discov 5: 660-670.
24. Miró X, Pérez-Torres S, Puigdomènech P, Palacios JM, Mengod G. 2002. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 45:259-269.
25. Moore CS, Owens T, Earl N, Frenette R, Styhler A, Nicholson DW, Mancini JA, Hebb AL, Robertson GS. 2006. Peripheral PDE4 inhibition produced by L-826,141 prevents experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 319:63-72.
26. Nadeau S, Rivest S. 1999. Regulation of the gene encoding tumor necrosis factor α (TNF-α) in the rat brain and pituitary in response in different models of systemic immune challenge. J Neuropathol Exp Neurol 58:61-77.
27. O'Donnell JM, Zhang HT. 2004. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 25:158-163.
28. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. San Diego: Academic Press.
29. 3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 20:349-374.
30. Pompeiano M, Palacios JM, Mengod G. 1992. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: Correlation with receptor binding. J Neurosci 12:440-453.
31. Quan N, Whiteside M, Kim L, Herkenham M. 1997. Induction of inhibitory factor κBα mRNA in the central nervous system after peripheral lipopolysaccharide administration: An in situ hybridization histochemistry study in the rat. Proc Natl Acad Sci USA 94:10985-10990.
32. Quan N, Stern EL, Whiteside MB, Herkenham M. 1999. Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol 93:72-80.
33. Reyes-Irisarri E, Perez-Torres S, Mengod G. 2005. Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 132:1173-1185.
34. Rose GM, Hopper A, De Vivo M, Tehim A. 2005. Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 11:3329-3334.
35. Scott AI, Perini AF, Shering PA, Whalley LJ. 1991. In-patient major depression: Is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 40:127-129.
36. Shepherd M, McSorley T, Olsen AE, Johnston LA, Thomson NC, Baillie GS, Houslay MD, Bolger GB. 2003. Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochem J 370:429-438.
37. Spina D. 2003. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63:2575-2594.
38. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. 1997. Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol Sci 18:164-171.
39. Uhlig S, Featherstone RL, Held HD, Nusing R, Schudt C, Wendel A. 1997. Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs. J Pharmacol Exp Ther 283:1453-1459.